Use of cholesterol-lowering agents to aggressively lower LDL cholesterol thereby delaying the need for catheter- based revascularisation

摘要

Use of a cholesterol-lowering agent such as an HMG-CoA reductase inhibitor for aggressively lowering LDL cholesterol, by at least 40% from baseline, in patients suffering from coronary artery disease prevents or delays the need for catheter-based revascularization. Cholesterol lowering agents may be selected from clofibrate, gemfibrozil, fenofibrate, ciprofibrate and benofibrate.